Navigation Links
Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
Date:4/28/2009

OSLO, Norway, April 28 /PRNewswire/ -- Affitech AS, the human antibody therapeutics company, announced today that preclinical data on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner Peregrine Pharmaceuticals at the 100th Annual Meeting of the American Association for Cancer Research (AACR) 2009 held during April 18 - 22, 2009 in Denver, CO. The preclinical studies of PGN635 and PGN632 provided further confirmatory evidence that the anti-tumor effects observed with anti-PS antibodies reflect their immunomodulatory mechanism of action, including their ability to stimulate the immune system. Additionally, PGN635 demonstrated encouraging signs of efficacy in a preclinical model of prostate cancer. Both antibodies were isolated using Affitech's unique MBAS (Molecule Based Antibody Screening) method for selection and improvement of fully human antibodies from large libraries.

The researchers from Peregrine, Affitech and UT Southwestern Medical Center confirmed previous observations that in vitro, anti-PS antibodies stimulate the tumor microenvironment to recruit monocytes and other immune cells to the tumor with resulting anti-tumor effects, most likely via cell-mediated mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC). Their data further defined the role of anti-PS antibodies in mediating tumor cell cytotoxicity and the tumor microenvironment, showing that the anti-PS antibody induced a sequential release of cytokines and beta-chemokines and stimulated enhanced macrophage recruitment to tumors. Furthermore, the researchers showed that in vitro, PGN635 induced antibody-dependent death of endothelial cells, the same cell type found in the tumor vasculature, a key target of anti-PS cancer therapy. The studies also demonstrated the anti-tumor potential of PGN635 in vitro and in a number of animal cancer models. Specifically, in a mouse model of prostate cancer, treatment with a mouse equivalent of PGN635 significantly retarded the growth of tumors by more than 90%.

In a separate study, researchers from UT Southwestern Medical Center (Peregrine's academic collaborators) and Affitech demonstrated in in vitro studies that immature dendritic cells cultured in the presence of PGN632 exhibited a significant increase in the production of inflammatory cytokines and chemokines. PGN632 also induced an increase in the expression of cell-surface molecules that are indicative of mature dendritic cells and that assist in antigen presentation functions, as well as in stimulating T-cell proliferation.

"These results demonstrate the efficiency and robustness of Affitech's range of antibody discovery platforms which include CBAS (Cell Based Antibody Screening) in addition to MBAS. They are being applied with increasing success to build proprietary oncology pipelines for both collaborators such as Peregrine and for ourselves," said Dr Martin Welschof, CEO of Affitech AS.

Commenting on the research progress of the antibodies and Peregrine's collaboration with Affitech, Steven King, President and CEO of Peregrine Pharmaceuticals said, "As leaders in the development of anti-PS antibodies for both oncology and anti-viral applications, we are delighted with these promising data for our fully human anti-PS antibodies from Affitech. They are the result of our well-established and highly productive collaboration and we look forward to continuing success in this and other projects."

For more information on Peregrine's anti-PS programs, visit http://www.peregrineinc.com


'/>"/>
SOURCE Affitech AS
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
4. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
5. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
6. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
7. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
8. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
11. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
Breaking Medicine Technology:
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):